A phase I study (BLOOM, NCT02228369), which has enrolled pretreated EGFR-mutant NSCLC patients with leptomeningeal metastasis treated with 160 mg osimertinib once daily, is ongoing. This evidence concerns the gene EGFR and non-small cell lung carcinoma.